Virtu Financial’s X4 Pharmaceuticals XFOR Stock Holding History

Virtu Financial’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53K	Sell	12,730 -9,759	-43%	-$36.6K	﹤0.01%	1281
2025 Q4	$90K	Buy	+22,489	New	+$81.7K	﹤0.01%	1224
2025 Q3	–	Sell	-12,587	Closed	-$24K	–	2167
2025 Q2	$24K	Buy	12,587 +10,343	+461%	+$42.3K	﹤0.01%	1239
2025 Q1	$16K	Buy	+2,244	New	+$30.9K	﹤0.01%	1139
2024 Q3	–	Sell	-1,685	Closed	-$29K	–	1951
2024 Q2	$29K	Buy	+1,685	New	+$55.1K	﹤0.01%	987
2024 Q1	–	Sell	-4,257	Closed	-$107K	–	2184
2023 Q4	$107K	Buy	+4,257	New	+$104K	0.01%	1018
2023 Q3	–	Sell	-503	Closed	-$29K	–	1985
2023 Q2	$29K	Sell	503 -3,280	-87%	-$169K	﹤0.01%	1212
2023 Q1	$99K	Buy	+3,783	New	+$111K	0.01%	986
2022 Q3	–	Sell	-680	Closed	-$20K	–	2297
2022 Q2	$20K	Sell	680 -186	-21%	-$7.08K	﹤0.01%	1332
2022 Q1	$45K	Buy	+866	New	+$49.7K	﹤0.01%	1165
2019 Q1	–	Sell	-196	Closed	-$82K	–	1909
2018 Q4	$82K	Buy	196 +69	+54%	+$26.3K	﹤0.01%	1180
2018 Q3	$37K	Buy	+127	New	+$53.9K	﹤0.01%	1346

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Virtu Financial's XFOR Position: Q1 2026 in Review

Virtu Financial reduced its X4 Pharmaceuticals (XFOR) stake by 43% in Q1 2026, selling an estimated $36.6K and leaving 12,730 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #1281.

Virtu Financial first reported a position in XFOR in Q3 2018 and has held it in 12 quarters since. The position peaked at $107K in Q4 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Virtu Financial held 12,730 shares of X4 Pharmaceuticals worth $53K as of Q1 2026.
Virtu Financial sold 9,759 X4 Pharmaceuticals shares in Q1 2026, an estimated $36.6K.
X4 Pharmaceuticals made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1281 holding.
Virtu Financial first reported a position in X4 Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Virtu Financial's X4 Pharmaceuticals position peaked at $107K in Q4 2023.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.